Mylan Pharmaceuticals Pvt Ltd has launched a portfolio of eight women's care products in India.
The initial offering focuses on therapies such as hormones, pre- and post-natal nutrition and management of premenstrual syndrome.
Mylan CEO Heather Bresch commented: “The launch of Mylan's Women's Care portfolio expands and strengthens our growing commercial platform in India.”
The company’s President Rajiv Malik said: “We expect to continue to expand into new therapeutic categories, further expand our field force and leverage our distribution capabilities in India.”
Mylan Pharmaceuticals, with a manufacturing base in Hyderabad, is a subsidiary of US-based Mylan Inc. It is engaged in manufacturing a comprehensive range of antiretroviral products. Mylan Inc, a leading generic and specialty pharmaceutical company, had acquired Indian company Matrix Laboratories in 2007. Mylan has a portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. It also produces a range of anti-retroviral therapies, upon which approximately 40 per cent of HIV/AIDS patients in developing countries depend, the company said in a press release.
somasekhar.m@thehindu.co.in
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.